Durvalumab with bile duct heat therapy for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of a drug (durvalumab) that helps your immune system fight cancer, plus a special heat treatment applied inside the bile duct. It is for people with bile duct cancer that cannot be removed by surgery and who need a stent to open the bile duct.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have bile duct cancer that cannot be surgically removed and you need a stent placed in the bile duct.
- You have already had one heat treatment (RFA) in the bile duct and it was okay for you.
- Your doctor says you are fit enough to receive chemotherapy.
- Your overall health is good (ECOG score 0 or 1), meaning you are fully active or only limited in strenuous activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heat therapy inside the bile duct (endobiliary RFA) with immunotherapy (durvalumab) and chemotherapy (gemcitabine and cisplatin) for people with unresectable extrahepatic cholangiocarcinoma. The goal is to see if adding the heat treatment improves outcomes.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This study tests a new way to treat a type of bile duct cancer (intrahepatic cholangiocarcinoma) using sound waves to destroy tumors. It also continues giving an immunotherapy drug called durvalumab. This combination may help control the cancer better and is for people whose cancer is not shrinking anymore after initial chemotherapy.
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery helps people with a high-risk type of bile duct cancer live longer. If you qualify, you would receive the drug combination before your planned surgery.
This trial tests a procedure that uses heat (radiofrequency ablation) to treat bile duct cancer that can't be removed by surgery. If you have this type of cancer and are starting standard treatment, this study wants to see if adding this heat treatment is safe and might help.
Hear when a new Extrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.